Lawson Kroeker Investment Management Inc. NE Sells 2,233 Shares of Enovis Co. (NYSE:ENOV)

Lawson Kroeker Investment Management Inc. NE decreased its position in shares of Enovis Co. (NYSE:ENOV) by 1.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 215,440 shares of the company’s stock after selling 2,233 shares during the quarter. Enovis makes up 1.8% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 19th largest holding. Lawson Kroeker Investment Management Inc. NE owned about 0.39% of Enovis worth $9,454,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Hantz Financial Services Inc. boosted its position in Enovis by 10.3% during the fourth quarter. Hantz Financial Services Inc. now owns 247,469 shares of the company’s stock valued at $10,859,000 after purchasing an additional 23,073 shares in the last quarter. Tributary Capital Management LLC boosted its position in Enovis by 33.9% during the fourth quarter. Tributary Capital Management LLC now owns 566,089 shares of the company’s stock valued at $24,840,000 after purchasing an additional 143,258 shares in the last quarter. Dynamic Advisor Solutions LLC boosted its position in Enovis by 7.8% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 18,999 shares of the company’s stock valued at $834,000 after purchasing an additional 1,377 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Enovis by 198.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 20,416 shares of the company’s stock valued at $896,000 after purchasing an additional 13,586 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Enovis during the fourth quarter valued at about $757,000. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Shares of NYSE:ENOV opened at $47.47 on Thursday. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The business has a 50-day moving average price of $46.07 and a 200-day moving average price of $44.51.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period last year, the company earned $0.56 earnings per share. As a group, equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th. JMP Securities assumed coverage on Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.